Tags

Type your tag names separated by a space and hit enter

Effects of omega-3 fatty acids on serum lipids, lipoprotein (a), and hematologic factors in hemodialysis patients.
Ren Fail. 2011; 33(9):892-8.RF

Abstract

BACKGROUND

Lipid abnormalities, especially high serum lipoprotein (a) [Lp (a)] concentration, and anemia are two major causes of cardiovascular diseases (CVDs) in hemodialysis patients. Therefore, this study was designed to investigate the effects of marine omega-3 fatty acids on serum lipids, Lp (a), and hematologic factors in hemodialysis patients.

METHODS

Thirty-four hemodialysis patients were randomly assigned to either omega-3 fatty acid supplement or placebo group. Patients in the omega-3 fatty acids group received 2080 mg marine omega-3 fatty acids, daily for 10 weeks, whereas the placebo group received a corresponding placebo. At baseline and the end of week 10, 7 mL blood was collected after a 12- to 14-h fast and serum triglyceride, total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), Lp (a), blood hemoglobin, hematocrit, red blood cells (RBCs), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC) were measured.

RESULTS

Serum triglyceride decreased significantly in the omega-3 fatty acids group at the end of week 10 compared with baseline (p < 0.05) and this reduction was significant in comparison with the placebo group (p < 0.01). No significant differences were observed between the two groups in mean changes of serum total cholesterol, LDL-C, HDL-C, Lp (a), blood hemoglobin, hematocrit, RBC, MCV, MCH, and MCHC.

CONCLUSION

The results of our study indicate that marine omega-3 fatty acids can reduce serum triglyceride, as a risk factor for CVD, but it does not affect other serum lipids, Lp (a), and hematologic factors in hemodialysis patients.

Authors+Show Affiliations

Department of Nutrition & Biochemistry, Sabzevar University of Medical Sciences, Sabzevar, Islamic Republic of Iran.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21859401

Citation

Kooshki, Akram, et al. "Effects of Omega-3 Fatty Acids On Serum Lipids, Lipoprotein (a), and Hematologic Factors in Hemodialysis Patients." Renal Failure, vol. 33, no. 9, 2011, pp. 892-8.
Kooshki A, Taleban FA, Tabibi H, et al. Effects of omega-3 fatty acids on serum lipids, lipoprotein (a), and hematologic factors in hemodialysis patients. Ren Fail. 2011;33(9):892-8.
Kooshki, A., Taleban, F. A., Tabibi, H., & Hedayati, M. (2011). Effects of omega-3 fatty acids on serum lipids, lipoprotein (a), and hematologic factors in hemodialysis patients. Renal Failure, 33(9), 892-8. https://doi.org/10.3109/0886022X.2011.605536
Kooshki A, et al. Effects of Omega-3 Fatty Acids On Serum Lipids, Lipoprotein (a), and Hematologic Factors in Hemodialysis Patients. Ren Fail. 2011;33(9):892-8. PubMed PMID: 21859401.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of omega-3 fatty acids on serum lipids, lipoprotein (a), and hematologic factors in hemodialysis patients. AU - Kooshki,Akram, AU - Taleban,Forough Azam, AU - Tabibi,Hadi, AU - Hedayati,Mehdi, Y1 - 2011/08/23/ PY - 2011/8/24/entrez PY - 2011/8/24/pubmed PY - 2012/2/4/medline SP - 892 EP - 8 JF - Renal failure JO - Ren Fail VL - 33 IS - 9 N2 - BACKGROUND: Lipid abnormalities, especially high serum lipoprotein (a) [Lp (a)] concentration, and anemia are two major causes of cardiovascular diseases (CVDs) in hemodialysis patients. Therefore, this study was designed to investigate the effects of marine omega-3 fatty acids on serum lipids, Lp (a), and hematologic factors in hemodialysis patients. METHODS: Thirty-four hemodialysis patients were randomly assigned to either omega-3 fatty acid supplement or placebo group. Patients in the omega-3 fatty acids group received 2080 mg marine omega-3 fatty acids, daily for 10 weeks, whereas the placebo group received a corresponding placebo. At baseline and the end of week 10, 7 mL blood was collected after a 12- to 14-h fast and serum triglyceride, total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), Lp (a), blood hemoglobin, hematocrit, red blood cells (RBCs), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC) were measured. RESULTS: Serum triglyceride decreased significantly in the omega-3 fatty acids group at the end of week 10 compared with baseline (p < 0.05) and this reduction was significant in comparison with the placebo group (p < 0.01). No significant differences were observed between the two groups in mean changes of serum total cholesterol, LDL-C, HDL-C, Lp (a), blood hemoglobin, hematocrit, RBC, MCV, MCH, and MCHC. CONCLUSION: The results of our study indicate that marine omega-3 fatty acids can reduce serum triglyceride, as a risk factor for CVD, but it does not affect other serum lipids, Lp (a), and hematologic factors in hemodialysis patients. SN - 1525-6049 UR - https://www.unboundmedicine.com/medline/citation/21859401/Effects_of_omega_3_fatty_acids_on_serum_lipids_lipoprotein__a__and_hematologic_factors_in_hemodialysis_patients_ L2 - https://www.tandfonline.com/doi/full/10.3109/0886022X.2011.605536 DB - PRIME DP - Unbound Medicine ER -